Skip to main content
Journal cover image

TARGETING FGFR FUSIONS: A CASE OF CATEQUENTINIB (AL3818) AND TEMOZOLOMIDE COMBINATION THERAPY FOR RECURRENT MGMT METHYLATED TACC-FGFR FUSION POSITIVE GLIOBLASTOMA

Publication ,  Conference
Seas, A; Patel, M; Kowalsky, M; Rudd, DS; Jacobs, SD; Miller, ES; Volas-Redd, GH; Johnson, MO
Published in: NEURO-ONCOLOGY
2023

Duke Scholars

Published In

NEURO-ONCOLOGY

EISSN

1523-5866

ISSN

1522-8517

Publication Date

2023

Volume

25

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1109 Neurosciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Seas, A., Patel, M., Kowalsky, M., Rudd, D. S., Jacobs, S. D., Miller, E. S., … Johnson, M. O. (2023). TARGETING FGFR FUSIONS: A CASE OF CATEQUENTINIB (AL3818) AND TEMOZOLOMIDE COMBINATION THERAPY FOR RECURRENT MGMT METHYLATED TACC-FGFR FUSION POSITIVE GLIOBLASTOMA. In NEURO-ONCOLOGY (Vol. 25).
Seas, Andreas, Mallika Patel, Martin Kowalsky, Daniel S. Rudd, Susanne D. Jacobs, Elizabeth S. Miller, Gena H. Volas-Redd, and Margaret O. Johnson. “TARGETING FGFR FUSIONS: A CASE OF CATEQUENTINIB (AL3818) AND TEMOZOLOMIDE COMBINATION THERAPY FOR RECURRENT MGMT METHYLATED TACC-FGFR FUSION POSITIVE GLIOBLASTOMA.” In NEURO-ONCOLOGY, Vol. 25, 2023.
Seas A, Patel M, Kowalsky M, Rudd DS, Jacobs SD, Miller ES, Volas-Redd GH, Johnson MO. TARGETING FGFR FUSIONS: A CASE OF CATEQUENTINIB (AL3818) AND TEMOZOLOMIDE COMBINATION THERAPY FOR RECURRENT MGMT METHYLATED TACC-FGFR FUSION POSITIVE GLIOBLASTOMA. NEURO-ONCOLOGY. 2023.
Journal cover image

Published In

NEURO-ONCOLOGY

EISSN

1523-5866

ISSN

1522-8517

Publication Date

2023

Volume

25

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1109 Neurosciences